Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers

Reuters

11/06

<a href="https://laohu8.com/S/RVMD">Revolution Medicines</a> Unveils Pipeline Advancements Targeting RAS-Driven Cancers

Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS$(ON)$ inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581884707"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581884707\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581884707?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581884707","market":"fut","top_or_hot":-1,"title":"Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3f60vf:1","article_id":"2581884707","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581884707","pubTimestamp":1762378338,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS inhibitors: daraxonrasib , elironrasib , and zoldonrasib . Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma  and non-small cell lung cancer , with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor  toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc.","BK4139":"生物科技"},"translate_title":"Revolution Medicines公布针对RAS驱动癌症的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":0.9},"content_text":"Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n    \n\n        Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS$(ON)$ inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}